Evidence map›Paper›PMID 20400988›Full record

ArticleBone marrow transplantation2011

A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies.

A Takami, J L Espinoza, M Onizuka, K Ishiyama, T Kawase, Y Kanda, H Sao, H Akiyama, K Miyamura, S Okamoto and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. The Impact of NLRP3 Activation on Hematopoietic Stem Cell Transplantation.International journal of molecular sciences · 2021
    Review
  3. Article
  4. Article
  5. Review
  6. Role of non-HLA gene polymorphisms in graft-versus-host disease.International journal of hematology · 2013
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 2 countries.

A TakamiDepartment of Hematology and Oncology, Kanazawa University Hospital, Kanazawa, Japan. takami@med3.m.kanazawa-u.ac.jp
J L Espinoza
M Onizuka
K Ishiyama
T Kawase
Y Kanda
H Sao
H Akiyama
K Miyamura
S Okamoto
M Inoue
S Ohtake
T Fukuda
Y Morishima
Y Kodera
S Nakao
Japan Marrow Donor Program
Kanazawa University · JPAichi Cancer Center · JPAichi Medical University · JPJichi Medical University · JPKanazawa University Hospital · JPKeio University · JPMeitetsu Hospital · JPNational Cancer Center · USOsaka Medical Center for Cancer and Cardiovascular Diseases · JPTokai University · JPTokyo Metropolitan Komagome Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fcγ receptor type IIIA (FCGR3A) has a functional single-nucleotide polymorphism (rs396991), at which a G-to T-point mutation results in an amino acid substitution at position 158 (valine to phenylalanine; V158F). This study examined the effect of the FCGR3A polymorphism in donors and recipients on the clinical outcomes in unrelated HLA fully matched myeloablative BMT. The FCGR3A-V158F genotype was retrospectively analyzed in a total of 99 recipients with myeloid malignancies, and their unrelated donors. The presence of the 158V genotype in recipients showed a statistically better OS (adjusted hazard ratio (HR) 0.49; 95% confidence interval (CI) 0.26-0.93; P=0.03) and TRM (HR 0.30; 95% CI 0.14-0.67; P=0.003) without significant influence on the relapse rate. The recipient 158V genotype was also associated with a significantly reduced risk of chronic GVHD (HR 0.45; 95% CI 0.20-0.99; P=0.049) and a trend toward a reduced risk of grade II-IV acute GVHD (HR 0.55; 95% CI 0.27-1.10; P=0.09), leading to a significantly reduced GVHD-related mortality (HR 0.22; 95% CI 0.06-0.77; P=0.02). The donor FCGR3A polymorphism did not have any effect on the transplant outcomes. These results suggest an association between the recipient FCGR3A genotype and the clinical outcomes after BMT.

Indexed as

Bone Marrow TransplantationHistocompatibility TestingPolymorphism, Single NucleotideAdolescentAdultChildChild, PreschoolFemaleGenotypeGraft vs Host DiseaseHumansInfantLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteMaleMiddle AgedFCGR3A protein, humanReceptors, IgG

Identifiers

PMID20400988
OpenAlexW1975405095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.